Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML
Go back to Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML| Consolidated Gems, Inc. (NASDAQ: CGEM) | Delayed: 17.51 +0.30 (1.74%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $17.21 | 52 Week High | $0.19 | |||
| Open | $17.35 | 52 Week Low | $0.03 | |||
| Day High | $17.79 | P/E | N/A | |||
| Day Low | $17.14 | EPS | $0.00 | |||
| Volume | 85,332 | |||||
